Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYG24002 Lotion in Mild to Moderate Seborrheic Dermatitis
NCT07404033Phase 1Recruiting
- Sponsor
- Sinomune Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZYG24002 in seborrheic dermatitis (SD) (4 arms), sponsored by Sinomune Pharmaceutical. Primary endpoints: Incidence rates of Serious Adverse Events at 1 year, Incidence rate of adverse events with severity grade >= 3 at 1 year and 7 more. Started Apr 2026; status: recruiting.
02
Drugs
ZYG24002
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT07404033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404033.